Looking for pharma growth? Here it is--in monoclonal antibodies. A new Datamonitor report projects 14 percent annual growth in the market for the antibody drugs, which mimic the body's own immune system. That's by far the fastest-growing segment of the industry.
It's easy to see why, when you recite a list of drugs that fall under this umbrella: Avastin, Herceptin, Remicade, Humira and Rituxan. Monoclonal antibodies sell at the rate of $20 billion annually; by 2009, Datamonitor predicts, that figure will be $34 billion. The only caveat? The "big five" drugs mentioned above will still account for most of the market--some 70 percent in 2012.
- check out the Datamonitor report [1] for more
Related Articles:
FDA approves Rituxan for rheumatoid arthritis. Report [2]
FDA approves Avastin for lung cancer. Report [3]
Remicade approved for psoriatic arthritis. Report [4]
FDA approves expanded use of Humira. Report [5]
Erbitux clears late-stage hurdle for lung cancer. Report [6]
Links:
[1] http://www.fiercebiotech.com/press-releases/press-release-mab-sector-growth-will-continue-far-outstrip-small-molecules?utm_medium=nl&utm_source=internal
[2] http://www.fiercebiotech.com/story/fda-approves-rituxan-for-rheumatoid-arthritis/2006-03-01?utm_medium=nl&utm_source=internal
[3] http://www.fiercebiotech.com/story/fda-approves-avastin-for-lung-cancer/2006-10-12?utm_medium=nl&utm_source=internal
[4] http://www.fiercebiotech.com/story/remicade-approved-for-psoriatic-arthritis/2006-08-14?utm_medium=nl&utm_source=internal
[5] http://www.fiercebiotech.com/story/fda-approves-expanded-use-of-humira/2005-10-04?utm_medium=rss&utm_source=biotech_Humira
[6] http://www.fiercebiotech.com/story/erbitux-clears-late-stage-hurdle-lung-cancer/2007-09-11?utm_medium=nl&utm_source=internal